Prostate carcinoma skeletal metastases: cross-talk between tumor and bone. Cancer Metastasis Rev ; 20 Alteration of the hormonal bioactivity of parathyroid hormone-related protein PTHrP as a result of limited proteolysis by prostate-specific antigen. Urology ; 48 Yang X, Karsenty G. Transcription factors in bone: developmental and pathological aspects.
Trends Mol Med ; 8 Coleman R, Seaman J. The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastasis. Semin Oncol ; 28 Berrettoni B. A, Carter JR. Mechanisms of cancer metastasis to bone. J Bone Joint Surg Am ; 68 Franks LM. The spread of prostatic carcinoma to the bones. J Pathol Bacteriol ; 66 Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.
Cell ; 76 Adhesion and homing of blood-borne cells in bone marrow microvessels. J Leukoc Biol ; 66 In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature ; Balkwill F. Cancer and the chemokine network. Nat Rev Cancer ; 4 Guo W, Giancotti FG.
Integrin signalling during tumour progression. Nat Rev Mol Cell Biol ; 5 CXCR4 expression in neuroblastoma primary tumors is associated with clinical presentation of bone and bone marrow metastases. J Pediatr Surg ; 39 Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: a retrospective case-control study. J Clin Oncol ; 24 Paget S. The distribution of secondary growths in cancer of the breast. Lancet ; 1 Coleman R, Rubens R.
The clinical course of bone metastases from breast cancer. Br J Cancer ; 55 Clinical course and prognostic factors following recurrence from breast cancer. Br J Cancer ; 17 Robson M, Dawson N. How is androgen dependent metastatic prostate cancer best treated?
Haematol Oncol Clinics North Am ; 10 Novel therapeutic approaches to cancer patients with bone metastasis. Crit Rev Oncol Hematol ; 40 Higinbotham N, Marcove R. The management of pathological fractures. J Trauma ; 5 Bone metastases: pathophysiology and management policy.
J Clin Oncol ; 9 Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol ; 22 Clohisy D, Mantyh P.
Bone cancer pain. Cancer ; 97 Bone health in cancer patients: ESMO clinical practice guidelines. Ann Oncol ; 25 Detection of vertebral metastases: comparison between MRI and bone scintigraphy.
Radiographics ; 11 Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev ; 22 Rosenthal D. Radiologic diagnosis of bone metastases. Cancer ; 80 Evans A, Robertson J. Magnetic resonance imaging versus radionuclide scintigraphy for screening in bone metastases. Clin Radiol ; 55 Staging non-small cell lung cancer with whole-body PET. Radiology ; Comparing whole-body 18FDG PET and technetiumm methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer.
J Cancer Res Clin Oncol ; Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med ; 40 Metastatic prostate cancer: initial findings of PET with 2-deoxy-2 F fluoro-d-glucose. Inhibition of growth of dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. This period of time has been marked by a number of key discoveries that have led to the opening up of entirely new areas for investigation as well as new therapies which combine surgery and biological therapeutic approaches.
Bone is a common site of cancer metastases - cancer cells commonly develop in bone and spread to other organ systems through the bloodstream. In clinical terms, bone metastases have substantial negative effects on a patient's quality of life and are a main cause of patient mortality. Given the global prevalence of breast and prostate cancers, knowledge of bone biology has become essential for the medical and cancer research communities. This book provides, all in one resource, the most recent data on bone cancer development cellular and molecular mechanisms , genomic and proteomic analyses, clinical analyses histopathology, imaging, pain monitoring , as well as new therapeutic approaches and clinical trials for primary bone tumors and bone metastases.
Feature Presents a comprehensive, translational source for all aspects of bone cancer in one reference work Bone cancer experts from all areas of research and practice take readers from the bench research cellular and molecular mechanism , through genomic and proteomic analysis, all the way to clinical analysis histopathology and imaging and new therapeutic approaches.
Clear presentation by bone biologists of the cellular and molecular mechanisms underlying bone tumors and bone cancer metastasis as well as the genomic and proteomic assays used in detecting cancer within given organ systems Clear presentation by oncologists and radiologists of how histopathology, imaging, and pain monitoring can lead to new therapeutic approaches Benefit Saves researchers and clinicians time in quickly accessing the very latest details on a broad range of bone cancer issues, as opposed to searching through thousands of journal articles.
Provides a common language for cancer researchers, bone biologists, oncologists, and radiologists to discuss bone tumors and how bone cancer metastases affects each major organ system Correct diagnosis and therefore correct treatment of cancer depends on a strong understanding of the molecular basis for the disease — both oncologists and radiologists will benefit Bone biologists will gain insight into how clinical observations and practices can feed back into the research cycle and will, therefore, be able to develop more targeted genomic and proteomic assays.
Bone biologists, cancer researchers, oncologists, orthopedic surgeons, radiologists and other specialists in cancer imaging; Medical libraries; graduate academic libraries. Hauben and Pancras C. Fournier, Lauren K. Dunn, Gregory A. Clines, Theresa A. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making.
Smith MR. Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer. Metabolic complications of androgen deprivation therapy for prostate cancer. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. Effects of gonadal steroid suppression on skeletal sensitivity to parathyroid hormone in men. Overview of bisphosphonates.
Bisphosphonate induces apoptosis and inhibits pro-osteoclastic gene expression in prostate cancer cells. Int J Urol. The Myeloma Aredia Study G Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma.
The Protocol 19 Aredia Breast Cancer Study G Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma.
J Clin Oncol. Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Reduction in new metastases in breast cancer with adjuvant clodronate treatment.
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. Schwarz E, Ritchlin C. J Bone Miner Res. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer.
Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. The effect of a single dose of osteoprotegerin in postmenopausal women. Phase I study of AMGN, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. A randomized phase III trial of denosumab versus zoledronic acid in patients with bone metastases from castration-resistant prostate cancer. Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials.
Lancet Oncol. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. Effectiveness of Zoledronic acid for the prevention of bone metastases in high-risk prostate cancer patients. A report of the ZEUS study.
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer. Ann Intern Med. The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: A randomized controlled trial.
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: Interim analysis of a multicenter phase 3 clinical study.
Application of a fracture risk algorithm to men treated with androgen deprivation therapy for prostate cancer. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer. Support Center Support Center. External link. Please review our privacy policy. Zometa 33 , Castration-resistant, asymptomatic or minimally symptomatic. Significant decrease in SREs No significant difference in pain, analgesic use, or SREs. No significant difference in palliative response, duration of response, progression-free survival, overall survival, overall quality of life.
Denosumab protocol Denosumab was superior to zoledronic acid; no difference in overall survival or adverse event rates. MRC PR05 49 , Ongoing Primary endpoint: SRE or prostate cancer death. MRC PR04 Castration-sensitive, localized, clinical stage T2-T4.
No difference in development of bone metastasis or overall survival. ZEUS Ongoing Primary objective: evaluate superiority of zoledronic acid over control in incidence of bone metastasis. Denosumab Protocol Castration-resistant, high risk by PSA criteria. Denosumab mg versus placebo, every 4 weeks. Ongoing Primary endpoint: bone metastasis-free survival Final results expected, Denosumab HALT Castration-sensitive, current androgen-deprivation therapy; no metastases; high risk for fracture.
Denosumab 60 mg versus placebo, every 6 months for 3 years. Toremifene Protocol G Strontium is an essential supplement that needs to be taken in addition to calcium. Strontium helps in converting calcium into the most useful form which helps in preserving healthy bones. Thusly, strontium indirectly aids in bone cancer cure. Magnesium also supports calcium and helps in maintaining healthy bones. Magnesium presence along with calcium in your body helps in better utilization of calcium and improves bone health.
Omega-3 fatty acid helps in preventing bone deterioration. Omega-3 fatty acids are generally present in fish oil in large quantity which helps in bone cancer cure.
Withania Somnifera also called ashwagandha is an ancient herb used as a natural cure for bone cancer. Ashwagandha boosts your immune system and improves bone health.
Ashwagandha is beneficial to cure different diseases, from mild to chronic ailments. Ashwagandha also has an antioxidant and anti-inflammatory property that can help in curing different infectious diseases. Curcumin is a common herb used to cure different types of cancers. Curcumin has antioxidant, anti-diabetic and anti-inflammatory properties that make the herb medicinally important in curing different disease conditions.
Curcumin also has an anti-biotic property and can fight against toxins. With all these medicinal properties, curcumin is used as an essential natural cure for bone cancer. Coral is used as a calcium store to improve bone strength. Coral is an ancient herb that helps in formation of strong bones and helps in curing bone cancer effectively. Giloy is a herb used in combination with coral to effectively cure bone cancer. Giloy boosts your immune system.
Calcium deficiency in your body can be effectively managed with this herb.
0コメント